WUXI
WXIDrugs in Pipeline
11
Phase 3 Programs
6
Upcoming Catalysts
4
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
4 upcoming, 0 past
Mesenchymal Stem Cells
Knee Osteoarthritis
CU-20101 treatment for Moderate to Severe Glabellar Striae
Glabellar Frown Lines
Lidocaine tetracaine cream
Analgesia
CU-40102 Spray
AGA
5 mg BGM0504 injection
Overweight or Obesity
Guideline-directed medical therapy (GDMT) for heart failure
Pulmonary Hypertension
NWRD08 administered by electroporation
High-grade Squamous Intraepithelial Lesion (HSIL)
D3S-001
KRAS P.G12C
CU-20401
Safety
Subcutaneous injection of CU-20401
Efficacy and Safety
D3S-002
Advanced Solid Tumors With MAPK Pathway Mutations
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mesenchymal Stem Cells | Phase 3 | Knee Osteoarthritis | - | - |
CU-20101 treatment for Moderate to Severe Glabellar Striae | Phase 3 | Glabellar Frown Lines | - | - |
Lidocaine tetracaine cream | Phase 3 | Analgesia | - | - |
CU-40102 Spray | Phase 3 | AGA | - | - |
5 mg BGM0504 injection | Phase 3 | Overweight or Obesity | - | - |
Guideline-directed medical therapy (GDMT) for heart failure | Phase 3 | Pulmonary Hypertension | - | - |
NWRD08 administered by electroporation | Phase 2 | High-grade Squamous Intraepithelial Lesion (HSIL) | - | - |
D3S-001 | Phase 2 | KRAS P.G12C | - | - |
CU-20401 | Phase 2 | Safety | - | - |
Subcutaneous injection of CU-20401 | Phase 2 | Efficacy and Safety | - | - |
D3S-002 | Phase 2 | Advanced Solid Tumors With MAPK Pathway Mutations | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in WUXI's drug pipeline?→
CatalystAlert tracks 11 drug candidates in WUXI's (WXI) pipeline across Phase 3, Phase 2. Its lead program is Mesenchymal Stem Cells (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is WUXI's next FDA catalyst?→
WUXI's (WXI) next tracked catalyst is a Phase 3 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track WXI biotech catalysts?→
Add WXI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow WUXI's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.